腹腔液基质金属蛋白酶-1、-2、-3、-9与子宫内膜异位症的相关性

目的探讨腹腔液基质金属蛋白酶(Matrixmet-alloproteinase,MMP)-1、-2、-3、-9在不同分期子宫内膜异位症患者腹腔液中的表达。方法收集61例行腹腔镜检查及治疗患者的腹腔液,其中35例为无子宫内膜异位症的对照组,18例为子宫内膜异位症Ⅰ、Ⅱ期患者,8例为子宫内膜异位症Ⅲ、Ⅳ期患者。用LiquiChip液相蛋白芯片系统对腹腔液标本中MMP-1、-2、-3、-9含量进行定量检测。结果腹腔液MMP-1在对照组,子宫内膜异位症Ⅰ、Ⅱ期组及子宫内膜异位症Ⅲ、Ⅳ期组分别为13.38、12.80、20.84ng/mL,MMP-2分别为19.42、19.54、24.39ng/mL,MMP-3分别为:118.47、117.35、141.65ng/mL,显示在前两组,腹腔液MMP-1、-2、-3表达接近,在子宫内膜异位症Ⅲ、Ⅳ期组高于前两组,但差异均无显著性(均P≥0.05);以上3组腹腔液MMP-9分别为41.23、23.06、30.85ng/mL,以子宫内膜异位症Ⅰ、Ⅱ期组最低,对照组最高,但3组差异无显著性(P>0.05)。结论腹腔液MMP-1、-2、-3表达升高,MMP-9表达降低与重度子宫内膜...

Expression of Matrix-metalloproteinase-1,-2,-3 and -9 in peritoneal fluid of endometriosis patients

Objective To evaluate the expression of Matrix metalloproteinase (MMP)-1,-2,-3 and -9 in the peritoneal fluid of different stage of endometriosis (EMs) patients. Methods Peritoneal fluid sampled from female without endometriosis (n=35) and (n=26) patients with endometriosis (18 cases with stageⅠ,Ⅱ;8 cases with stage Ⅲ, Ⅳ) were obtained for quantification of MMP-1,-2,-3,-9 by flexible Multi-Analyte Profiling (xMAP) method. Results The concentration of MMP-1 was 20.84, 12.80 and 13.38 ng/ml in stage Ⅲ, Ⅳ group, stageⅠ,Ⅱ group and control group, respectively., while MMP-2 was 24.39, 19.58 and 19.42 ng/ml, respectively, and MMP-3 were 141.65, 117.35 and 12.38 ng/ml, respectively. The concentration of MMP-9 was significantly different from that of MMP-1,-2,-3, and was the highest in control group (41.23 ng/ml) and the lowest in stageⅠ,Ⅱ group(23.06 ng/ml),and was 30.85 ng/ml in stage Ⅲ, Ⅳ group. However, no significant difference was revealed in all these markers among the groups. (P>0.05) Conclusion MMP-1,-2,-3 and -9 may play a role in the pathogenesis and development of severe endometriosis.